Cat No.
CEI-0009
Description
Pazopanib (GW786034B; GlaxoSmithKline) is a novel multi-targeted, orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor 1, VEGF receptor 2, and VEGF receptor 3 with IC50 values of 10, 30, and 47 nM.
Alias
GW786034
Synonyms
GW786034
CAS No.
635702-64-6
Targets
VEGFR1, VEGFR2, VEGFR3
Chemical Name
5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide hydrochloride
M.Wt
473.98
Purity
>99%
Solubility
DSMO 70 mg/mL Water 17 mg/mL Ethanol
Storage
2 years at -20 centigrade
In vitro
Pazopanib (GW786034B; GlaxoSmithKline) is a novel multi-targeted, orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor 1, VEGF receptor 2, and VEGF receptor 3 with IC50 values of 10 nM, 30 nM, and 47 nM. Pazopanib (GW786034B; GlaxoSmithKline) also shows inhibition to platelet-derived growth factor receptor (including PDGFR-alpha and PDGFR-beta), and c-kit, FGF-R1, and c-fms with IC50 of 84, 74, 140, and 146 nM. Pazopanib can inhibit MM cell growth, survival, and migration. It can inhibit MM cell lines including dexamethasone-sensitive MM.1S, dexamethasone resistant MM.1R, doxorubicin (Dox)-sensitive RPMI, Dox-resistant RPMI (Dox40), IL-6-dependent INA-6, OPM2, and U266. Pazopanib suppresses VEGF-Induced Endothelial Cell Proliferation and Migration.
